National Cancer Institute chief tapped as acting FDA Commissioner

In the wake of FDA commissioner Scott Gottlieb’s commissioner-scott-gottlieb-just-abruptly-resigned-from-his-post/">abrupt resignation, Secretary of Health and Human Services Alex M. Azar III announced that Dr. Ned Sharpless will serve as interim commissioner of the Food and Drug Administration.

Since October 2017, Dr. Sharpless served as Director of the National Cancer Institute and, before that, worked as a researcher and hematologist-oncologist at the University of North Carolina. He is also a cofounder of G1 Therapeutics, a biotech firm focused on cancer treatment therapies that went public in May of 2017.

Dr. Sharpless is a temporary appointment, with Secretary Azar saying that the search is on for a permanent candidate for the position, according to the NYT.

(1/3) Change is good, but bittersweet. It is difficult for me to say goodbye to @theNCI family as I head to @FDA to serve as acting commissioner. Rest assured that our shared goals for patients and the public’s health will translate into my new duties.

Dr. Ned Sharpless (@NCIDirector) March 12, 2019

The change comes at a tumultuous time for the e-cigarette industry in particular, which has been a focal point for commissioner Gottlieb. As vaping continues to grow in popularity among teens, Gottlieb has enforced new rules for the industry and promised to keep a close watch on youth use of these products and the companies that sell them.

Gottlieb praised the appointment:

I’m delighted by the announcement from @SecAzar that @NCIDirector will serve as acting commissioner of #FDA. Ned is a friend to FDA, a great public health champion, a dedicated physician, and will be warmly welcomed into his new role. FDA will benefit greatly from his leadership.

Scott Gottlieb, M.D. (@SGottliebFDA) March 12, 2019

Whether or not an acting commissioner will be able to push forward initiatives related to the tobacco industry, such as limiting the nicotine in combustible cigarettes and enforcing stricter regulation on e-cigs, is unclear. However, Altria shares fell on the news.

For those concerned @SGottliebFDA’s priorities on e-cigarettes/tobacco wouldn’t continue when he left, @NCIDirector Sharpless has been a supporter of those policies. Altria, Philip Morris International shares erased gains on the news. Here’s Altria pic.twitter.com/0CYSBQcBhM

Anna Edney (@annaedney) March 12, 2019